Unique ID issued by UMIN | UMIN000002422 |
---|---|
Receipt number | R000002966 |
Scientific Title | Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients |
Date of disclosure of the study information | 2009/09/07 |
Last modified on | 2009/09/01 14:30:17 |
Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients
Pleiotropic effect of telmisalthan and olmethaltan
Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients
Pleiotropic effect of telmisalthan and olmethaltan
Japan |
Chronic kidney disease stage 3-5
Nephrology |
Others
NO
The angiotensin receptor blockers (ARBs) exert their antihypertensive effect through blockage of the angiotensin II as the class effect and have a true pleiotropic drug effects. The purpose of the study is to estimate the impact of telmisartan and olmesartan on inflammation and oxidative stress in CKD patients (CKD stage 3-5).
Efficacy
The primary outcome is the impact of termisartan and olmesartan on blood pressure, proteinuria at four and twelve months after administration of the ARB case compared with at baseline.
The secondary outcome is the impact of termisartan and olmesartan on inflammatory and oxidative stress markers (hsCRP, IL-6, IL-10. TNF, pectsidine, PTX3, MPO, 8OHdG in urine)at four and twelve months after administration of the ARB case compared with at baseline
Interventional
Single arm
Non-randomized
Open -no one is blinded
Active
1
Treatment
Medicine |
olmesartan
20 | years-old | <= |
Not applicable |
Male and Female
1) Renal dysfunction: CKD stage 3-5
2) Expected survival time is more than 6 months
3) Aged 20 years over
4) Fully informed consent was obtained
1) Patients who has past history of adverse effect of taking another ARB
2) Pregnancy
3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome
4) Judged inappropriate for this study by the physicians
30
1st name | |
Middle name | |
Last name | Hirokazu Honda |
Showa University School of Medicine
Division of Nephrology , Depertment of Medicine
1-5-8, Hatanodai, Shinagawaku, Tokyo, Japan
1st name | |
Middle name | |
Last name | Hirokazu Honda |
Showa University School of Medicine
Division of Nephrology Department of Medicine
hondah@med.showa-u.ac.jp
Division of Nephrology Department of Medicine, Showa University School of Medicine
Division of Nephrology Department of Medicine Showa University School of Medicine
Self funding
NO
2009 | Year | 09 | Month | 07 | Day |
Unpublished
Open public recruiting
2009 | Year | 08 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2010 | Year | 12 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
2009 | Year | 09 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002966
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |